In this podcast episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss data on the potential use of monoclonal antibodies (mAb) for the prevention and treatment of COVID-19, including:Rationale for use of mAbPotential for resistance to mAbSingle vs combination therapy with mAbChallenges in implementation of mAb as treatment or preventionBamlanivimabSotrovimabCasirivimab plus imdevimabLink to full program, including downloadable slidesets: https://bit.ly/3zVTwYWPresenters: Sharon R. Lewin, AO, FRACP, PhD, FAHMSDirector, The Peter Doherty Institute for Infection and ImmunityProfessor of Infectious DiseasesFaculty Medicine Dentistry and Health SciencesUniversity of Melbourne and Royal Melbourne HospitalConsultant Infectious Diseases PhysicianDepartment of Infectious DiseasesRoyal Melbourne Hospital and Alfred HospitalMelbourne, AustraliaArthur Kim, MDAssociate ProfessorDepartment of MedicineHarvard Medical SchoolDirector, Viral Hepatitis ClinicDivision of Infectious DiseasesMassachusetts General HospitalBoston, MassachusettsSharon R. Lewin, AO, FRACP, PhD, FAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.Arthur Kim, MD, has disclosed that he has served on the drug and safety monitoring board for Kintor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related